Suparna R Krishnaiengar, M.D.
Associate Professor; Associate Program Director, Neurology Residency
Department:
Neurology – Jacksonville
Business Email:
suparna.krishnaiengar@jax.ufl.edu
About Suparna R Krishnaiengar
Suparna Krishnaiengar, M.D., is a University of Florida assistant professor of neurology and a neurologist at the UF Health Neuroscience Institute in Jacksonville specializing in clinical neurophysiology and epilepsy. She also serves as associate program director for the Neurology Residency Program.
Dr. Krishnaiengar received her medical degree from the University of Mysore in Mysore, India. She completed residency training in neurology, as well as a fellowship in clinical neurophysiology, at Oklahoma University Health Sciences Center in Oklahoma City, Oklahoma. She also completed a fellowship in clinical neurophysiology, electroencephalography and epilepsy at the Cleveland Clinic Foundation in Cleveland, Ohio. Dr. Krishnaiengar is board-certified in neurology, clinical neurophysiology and epilepsy.
Additional Positions:
Associate Program Director
2017 – Current
·
Neurology Residency
Associate Professor of Neurology
2011 – Current
·
University of Florida
Accomplishments
Exemplary Teacher Award
2020
·
University of Florida College of Medicine – Jacksonville
Teaching Profile
Courses Taught
2021
MDC7800 Neurology Clerkship
Board Certifications
-
Clinical NeurophysiologyAmerican Board of Psychiatry and Neurology
-
EpilepsyAmerican Board of Psychiatry and Neurology
-
NeurologyAmerican Board of Psychiatry and Neurology
Clinical Profile
Specialties
- Neurology
Subspecialties
- Clinical Neurophysiology
- Epilepsy
Publications
Academic Articles
2024
Lance Adams Syndrome in the Setting of COVID-19 Pneumonia.
Cureus.
16(5)
[DOI] 10.7759/cureus.60621.
[PMID] 38903282.
2023
Long-term quality of life in patients with focal seizures treated with adjunctive eslicarbazepine acetate.
Epilepsy & behavior : E&B.
148
[DOI] 10.1016/j.yebeh.2023.109466.
[PMID] 37839247.
2023
Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.
Clinical neurology and neurosurgery.
225
[DOI] 10.1016/j.clineuro.2022.107552.
[PMID] 36657359.
2021
Prolonged post-ictal atrial fibrillation following seizures.
Epilepsy & behavior reports.
16
[DOI] 10.1016/j.ebr.2021.100481.
[PMID] 34693244.
2019
Adult Presentation of Ornithine Transcarbamylase Deficiency: 2 Illustrative Cases of Phenotypic Variability and Literature Review.
The Neurohospitalist.
9(1):30-36
[DOI] 10.1177/1941874418764817.
[PMID] 30671162.
2011
Seizure semiology and aging.
Epilepsy & behavior : E&B.
20(2):375-7
[DOI] 10.1016/j.yebeh.2010.12.033.
[PMID] 21273137.
Grants
Apr 2022
ACTIVE
AN OPEN-LABEL, MULTICENTER, OUTPATIENT EXTENSION
STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF
STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS
12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL
PROLONGED SEIZURES
Role: Principal Investigator
Funding: UCB BIOPHARMA SRL
Apr 2022
ACTIVE
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED,
MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO
ASSESS THE EFFICACY AND SAFETY OF STACCATO
ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE
AND OLDER WITH STEREOTYPICAL PROLONGED
SEIZURES
Role: Principal Investigator
Funding: UCB BIOPHARMA SRL
May 2020
– Feb 2023
AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL PTY
via UCB BIOSCIENCES
Mar 2020
– Nov 2023
A Randomized, Double-blind, Placebo-controlled,
Multicenter Study to Evaluate the Safety, Tolerability
and Efficacy of XEN1101 as Adjunctive Therapy in
Focal-onset Epilepsy
Role: Principal Investigator
Funding: NCGS
via XENON PHARMACEUTICALS
Apr 2019
– Feb 2023
A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL PTY
via UCB BIOSCIENCES
Education
Epilepsy Fellowship
2009
·
Cleveland Clinic Foundation
Clinical Neurophysiology Fellowship
2008
·
Oklahoma University Health Sciences Center
Neurology Residency
2007
·
Oklahoma University Health Sciences Center
Bachelor of Medicine, Bachelor of Surgery
1994
·
University of Mysore
Contact Details
Emails:
- Business:
- suparna.krishnaiengar@jax.ufl.edu
Addresses:
- Business Mailing:
-
653 W 8TH ST
JACKSONVILLE FL 32209